We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Themis Bioscience Completes Series A Financing Round - EUR 5 Million to Advance Promising Vaccine Candidates

News   May 30, 2011

 
Themis Bioscience Completes Series A Financing Round - EUR 5 Million to Advance Promising Vaccine Candidates
 
 
Advertisement
 

RELATED ARTICLES

Exploring Functional Neurological Disorder and Vaccines

News

Videos of people experiencing severe neurological symptoms, including convulsions and difficulty walking, purportedly after receiving a COVID-19 vaccine, have surfaced on social media channels. The millions of people watching these videos might conclude that the vaccine is either quite dangerous to produce such symptoms or that the people in the videos are faking their symptoms. Both conclusions are incorrect, according to neurologist and psychiatrist David Perez.

READ MORE

Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types

News

Treatment with the neoantigen cancer vaccine PGV-001 following standard-of-care adjuvant therapy was well tolerated and demonstrated potential clinical benefit in patients with diverse tumor types according to a Phase 1 study. The findings were reported during the virtual AACR Annual Meeting 2021.

READ MORE

Oxford–AstraZeneca COVID-19 Vaccine: Regulators Give Update on Links to Rare Clotting Disorders

News

Dual announcements from regulators in the EU and the UK have jointly concluded that the Oxford–AstraZeneca vaccine, now trademarked as Vaxzevria, is effective at preventing COVID-19 and, overall, has benefits that outweigh any risk posed by extremely rare clotting disorders linked to the vaccine.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE